Abstract Background Despite significant advances in tissue engineering and regenerative medicine, articular cartilage repair remains a major clinical challenge. Conventional pharmacological and surgical interventions are largely ineffective in promoting durable tissue regeneration or halting progressive cartilage degradation. Sources of data This review integrates evidence from recent peer-reviewed literature focusing on nanotechnology-based drug delivery, stem cell–based therapy, and biomimetic scaffold design for cartilage tissue engineering. Areas of agreement There is a broad consensus that current standard treatments fail to restore native cartilage structure and function. The literature supports the view that integrating nanomedicine with tissue engineering strategies can enhance chondrogenic outcomes. In particular, nanocarriers enable targeted and controlled delivery of bioactive molecules, while synthetic extracellular matrix–mimicking scaffolds provide essential structural and biochemical cues for chondrogenesis. Areas of controversy Key unresolved issues include identifying the optimal stem cell source, the long-term safety and biodegradability of nanomaterials, and the scalability of engineered constructs for clinical use. The immunogenicity of advanced biomaterials and the regulatory challenges associated with their clinical translation remain subjects of debate. Growing points Recent studies demonstrate the feasibility of integrating nanocarriers within three-dimensional biomimetic scaffolds to better replicate the native cartilage microenvironment. Advances in biofabrication techniques and in situ delivery systems are enabling the development of more physiologically relevant and functional cartilage models. Areas timely for developing research Future research should prioritize in vivo validation of bio-activated scaffolds, comprehensive assessment of long-term functional outcomes, and strategies to facilitate clinical translation of combined nanocarrier–scaffold platforms. Further investigation into both patient-specific and off-the-shelf regenerative approaches is essential to overcome current translational barriers.
Lamparelli et al. (Fri,) studied this question.